How Does Tresiba Work? Mechanism of Action Explained in Plain English

Tresiba (insulin degludec) is remarkable for how it works. While most long-acting insulins last 18-24 hours, Tresiba stays active in your body for over 42 hours — without any pronounced peak in activity. This unique profile is what makes it so different from its predecessors and why it's become a preferred choice for many patients and providers.

Understanding how Tresiba works can help you use it more effectively, recognize what's happening in your body, and make more informed conversations with your doctor.

Why Do People with Diabetes Need Insulin?

Insulin is a hormone produced by the pancreas. Its main job is to act like a "key" that lets glucose (sugar) from the bloodstream enter your body's cells, where it's used for energy. Insulin also signals the liver to stop releasing stored glucose into the blood.

In type 1 diabetes, the immune system destroys the insulin-producing cells in the pancreas, so the body produces no insulin at all. In type 2 diabetes, the body either doesn't produce enough insulin or the cells become resistant to its effects. In both cases, blood sugar can rise to dangerous levels without insulin replacement or support.

What Makes Insulin Degludec (Tresiba) Unique?

Tresiba is a modified form of human insulin. Scientists at Novo Nordisk engineered it by removing a single amino acid from the insulin molecule and attaching a long fatty acid chain (hexadecanedioic acid) at a specific position (B29). This modification sounds minor but creates profound changes in how the insulin behaves in the body.

The Multi-Hexamer Mechanism: Why Tresiba Lasts So Long

Here's what happens step by step when you inject Tresiba:

Injection: You inject Tresiba under the skin (subcutaneously). The solution enters the tissue just below the skin.

Multi-hexamer formation: The fatty acid chains on insulin degludec molecules interact with each other and with albumin (a protein in your blood and tissues). This causes thousands of insulin molecules to link together into long chains called multi-hexamers. Think of it like individual chain links connecting to form a very long chain.

Subcutaneous depot formation: These multi-hexamer chains cluster together to form a stable "depot" (reservoir) under the skin at the injection site. This depot is where the insulin waits to be released.

Slow, steady release: Individual insulin molecules slowly break off from the ends of these chains and enter the bloodstream. The rate of release is slow and remarkably consistent — producing the flat, peakless action profile that defines Tresiba.

Bloodstream circulation and action: Once in the bloodstream, insulin degludec binds to insulin receptors on cells throughout the body. This signals cells to absorb glucose from the blood and signals the liver to stop releasing stored glucose — lowering blood sugar.

Why Is There No Peak?

Most insulins are absorbed from the injection site at a variable rate, producing a "peak" — a period of maximum blood-sugar-lowering activity — a few hours after injection. This peak can cause hypoglycemia if it coincides with a time when you haven't eaten or if the dose is slightly too high.

Tresiba's multi-hexamer depot releases insulin at a slow, constant rate — so there's no burst of insulin activity. The blood-sugar-lowering effect is spread evenly over 42+ hours. This is why the DEVOTE clinical trial showed Tresiba reduced severe hypoglycemia by 40% compared to insulin glargine — without the peak, there are fewer dangerous dips.

How Does Tresiba Compare to Other Basal Insulins?

Lantus (insulin glargine U-100): Lasts ~24 hours, relatively flat but shorter duration. Works by forming a microprecipitate at the injection site (different mechanism from Tresiba's multi-hexamers).

Toujeo (insulin glargine U-300): Same active ingredient as Lantus but at 3x the concentration. Lasts up to 36 hours with a flatter profile — pharmacokinetically closer to Tresiba.

Levemir (insulin detemir — discontinued): Lasted 18-24 hours, required twice-daily dosing for many patients. Extended by binding to albumin in the blood.

Tresiba reaches steady-state concentration in the blood after 3-4 days of once-daily injections. At steady state, its action is remarkably consistent and predictable — one of the reasons clinicians often choose it for patients with significant hypoglycemia concerns.

Finding Tresiba If It's Hard to Get

Tresiba has been in intermittent shortage in 2025-2026. If you can't find it at your pharmacy, medfinder checks multiple pharmacies near you at once and texts you the results. For more info, see our full guide: Why Is Tresiba So Hard to Find? [Explained for 2026].

For a complete overview of Tresiba including dosage and who it's for, see: What Is Tresiba? Uses, Dosage, and What You Need to Know in 2026.